Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Treatment/Intervention:  neoadjuvant therapy
Results 1-25 of 37 for your search:
Start Over
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011106, NCI-2013-01340, NCT01953588
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IFHCC 09-002, NCI-2014-01429, NCT01023477
Durvalumab and Combination Chemotherapy in Treating Patients with Stage I-III Triple Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1409014537, NCI-2016-00070, ESR-14-10265, NCT02489448
Docetaxel or Doxorubicin Hydrochloride and Cyclophosphamide Before Surgery in Treating Patients With Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: H-16039, NCI-2012-00652, NCT00206518
Anastrozole With or Without Fulvestrant in Treating Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-20431, NCI-2012-00645, NCT00570323
Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Bevacizumab or Trastuzumab Before Surgery in Treating Women With Stage I-III Breast Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 21 to 90
Trial IDs: UCI-07-61, NCI-2010-00155, 2007-6084, NCT00618657
Laboratory Treated T Cells after Chemotherapy in Treating Patients with HER2-Negative Stage II-III Breast Cancer That Can Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-056, NCI-2011-02634, 1005008403, CDR0000675211, NCT01658969, WSU-2010-056, NCT01147016
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Locally Advanced or Inflammatory Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11174, NCI-2012-00025, 103352, 109696, 110312, 118191, NCT01525966
Cisplatin or Doxorubicin Hydrochloride and Cyclophosphamide before Surgery in Treating Patients with Newly Diagnosed Breast Cancer and BRCA Mutations
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-258, NCI-2012-02217, TBCRC031, NCT01670500
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201301106, NCI-2012-02202, NCT01723774
Paclitaxel and Cyclophosphamide with or without Trastuzumab before Surgery in Treating Patients with Previously Untreated Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 264-12, NCI-2012-01372, NCT01750073
Propranolol Hydrochloride, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients with Newly Diagnosed Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAAI9158, NCI-2013-01045, NCT01847001
Pertuzumab and Trastuzumab with Combination Chemotherapy before Surgery in Treating Patients with Stage I-III HER2 Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 1305012136, NCI-2015-02018, ML28772, NCT01855828
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
Cisplatin or Paclitaxel before Surgery in Treating Patients with Triple Negative Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-383, NCI-2014-00955, 030, TBCRC 030, NCT01982448
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients with Docetaxel and Carboplatin to Assess Anti-tumor Activity
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201404107, NCI-2014-01037, NCT02124902
Aromatase Inhibitors with Everolimus before Surgery in Treating Postmenopausal Patients with Hormone Receptor Positive, HER2 Negative, Stage II-IIIC Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CRAD001JUS228T, NCI-2014-02280, 1405013982, NCT02236572
A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GO28888, NCI-2014-02653, 2013-000568-28, NCT02273973
BMN-673 before Standard Therapy in Treating Patients with Invasive, BRCA-Mutated Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0045, NCI-2015-00335, NCT02282345
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-11, NCI-2015-00998, WI180455, NCT02296801
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29505, NCI-2015-01653, 2014-003029-16, NCT02301988
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients with Triple Negative Stage II-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 041401, NCI-2014-02029, NCT02315196
Carboplatin and Docetaxel or Carboplatin and Paclitaxel Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with Stage I-III Triple-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2014-BRST-TNBC-LQT, NCI-2015-01416, STUDY00002467, NCT02413320
Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 14-67, NCI-2015-02066, NCT02436993
Start Over